

Patient Name:

Height (inches):

Date of Birth:

Weight (lbs):

# Skyrizi (risankizumab-rzaa)

Non-Oncology Treatment Order Set  
Drug order form is valid for 12-months

Please complete all fields to facilitate timely intake and prior authorization processing.

1. **DIAGNOSIS** \*MUST match recent office visit note\*

Please include an addendum or letter of medical necessity, if appropriate.

**K50.0** – Crohn's Disease

**K51.9** – Ulcerative Colitis

Other ICD-10 Code:

Description:

**DIAGNOSIS DATE:**

2. **PRE-MEDICATION**

Pre-medication:

No Pre-medications indicated

3. **DRUG ORDER**

**Skyrizi (risankizumab-rzaa)**

Induction: 600 mg IV weeks 0, 4, and 8 (**Crohn's**)

Induction: 1200 mg IV weeks 0, 4 and 8 (**Ulcerative Colitis**)

Special Instructions:

**Therapy Status**

**NEW** to therapy

**Continuing** therapy-

Last dose received:

Next dose due:

Copy of Medication Administration Record is attached

4. **REQUIRED LABS**

CBC

LFTs

Other:

None indicated

**\*\*HOACNY WILL NOT DRAW LAB WORK REQUIRED FOR INFUSION ADMINISTRATION\*\***

The **prescribing physician** is responsible for ordering, obtaining, reviewing all laboratory results & providing copy to HOACNY prior to infusion as ordered above.

Patient Name:

Height (inches):

Date of Birth:

Weight (lbs):

**5. LAB-INFUSION PARAMETERS**

Our policy is to administer this medication as long as **liver function** (AST, ALT, bilirubin and alkaline phosphatase) and **CBC** are within normal limits. If any additional monitoring parameters are required, please specify below:

**6. COMPLETED BASELINE LABS & TESTS \*Fax all results to HOACNY\***

CBC + CMP

TB Status

C-reactive protein

Hepatitis B Screening (surface antigen, surface antibody, and core antibody are recommended)

Hepatitis C Screening:  Obtained - OR -  Waived

HIV Screening:  Obtained - OR -  Waived

Pregnancy Test:  Obtained  Waived  Not Applicable

Other:

**POLICY ACKNOWLEDGEMENT**

To maintain ongoing authorization, updated clinical documentation is required every 6-months and a new drug order form is required annually. Updated documentation will be required for all dose and/or frequency changes.

HOACNY will obtain authorization for drug administration prior to scheduled infusion. If HOACNY is unable to obtain insurance authorization due to this medication not being in alignment with the insurance plan's medical policy, the referring office will be notified and HOACNY will not be able to administer the medication. HOACNY may use a biosimilar or generic medication based on insurance company's preferred biosimilar medications or practice preferred medications. The biosimilar medication used may change during the course of treatment depending on those preferences. HOACNY does not participate in free drug programs.

HOACNY is responsible to provide nursing care, safe drug handling & administration, post-infusion observation and management of hypersensitivity reactions per the HOACNY Infusion Policy & Procedure Guidelines. The prescribing physician is responsible for educating the patient of potential risks and complications associated with the drug administration as well as drug specific monitoring parameters before proceeding with Non-Oncology Medication Infusion Services referral. The prescribing provider is responsible for identifying and managing any side effects of the prescribed medication and for determining whether it is appropriate to proceed with treatment. Please call our office to coordinate with our Infusion Services Nurse Navigator, as appropriate. Any changes in condition or delayed adverse events that occur after leaving the infusion center will be reported to the prescribing physician for evaluation & management.

Provider's Name:

Phone:

Provider's Signature:

Date: